{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Galapagos NV"},"Symbol":{"label":"Symbol","value":"GLPG"},"Address":{"label":"Address","value":"GENERAAL DE WITTELAAN L11 A3, MECHELEN, 2800, Belgium"},"Phone":{"label":"Phone","value":"+32 15342900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis."},"CompanyUrl":{"label":"Company Url","value":"https://www.glpg.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Paulus Stoffels","title":"Chairman & Chief Executive Officer"},{"name":"Robert Hughes","title":"Global Head-Technical Operations"},{"name":"Thad Huston","title":"Executive VP, Chief Operating & Financial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}